Sugar administration is an effective adjunctive therapy in the treatment of Pseudomonas aeruginosa pneumonia

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 305, Issue 5, 2013, Pages

  Bucior, Iwona ^a,b   Abbott, Jason ^a,b   Song, Yuanlin ^a,b   Matthay, Michael A ^a,b   Engel, Joanne N ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibiotics; Microbial pathogenesis; Pneumonia; Pseudomonas aeruginosa; Therapeutics

Indexed keywords

BETA LACTAM DERIVATIVE; FUCOSE; GALACTOSE; MANNOSE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIUM ADHERENCE; BACTERIUM CULTURE; BRONCHUS MUCOSA; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; EPITHELIUM CELL; EX VIVO STUDY; IN VITRO STUDY; INFLAMMATION; LIQUID CULTURE; LUNG INJURY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA;

ANTIBIOTICS; MICROBIAL PATHOGENESIS; PNEUMONIA; PSEUDOMONAS AERUGINOSA; THERAPEUTICS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL ADHESION; BRONCHI; CARBOHYDRATES; CELLS, CULTURED; CYSTIC FIBROSIS; FUCOSE; GALACTOSE; HUMANS; INTERLEUKIN-8; LUNG INJURY; MALE; MANNOSE; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; PNEUMONIA, BACTERIAL; POLYSACCHARIDES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TRACHEA;

EID: 84883404345     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00387.2012     Document Type: Article

References (41)

1. Adam EC, Mitchell BS, Schumacher DU, Grant G, Schumacher U. Pseudomonas aeruginosa II lectin stops human ciliary beating: therapeutic implications of fucose. Am J Respir Crit Care Med 155: 2102-2104, 1997.
2. Aitken ML, Bellon G, De Boeck K, Flume PA, Fox HG, Geller DE, Haarman EG, Hebestreit HU, Lapey A, Schou IM, Zuckerman JB, Charlton B. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 185: 645-652, 2012.
3. Allison KR, Brynildsen MP, Collins JJ. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 473: 216-220, 2011.
4. Balasubramanian D, Kong KF, Jayawardena SR, Leal SM, Sautter RT, Mathee K. Coregulation of β-lactam resistance, alginate production and quorum sensing in Pseudomonas aeruginosa. J Med Microbiol 60: 147-156, 2011.
5. Borlee BR, Goldman AD, Murakami K, Samudrala R, Wozniak DJ, Parsek MR. Pseudomonas aeruginosa uses a cyclic-di-GMP-regulated adhesin to reinforce the biofilm extracellular matrix. Mol Microbiol 75: 827-842, 2010.
6. Bucior I, Engel J. The type IV pili and flagellar adhesins of Pseudomonas aeruginosa bind to and internalize through distinct receptors on the apical and basolateral surface of airway epithelium. PLoS Pathog 8: e1002616, 2012.
7. Bucior I, Mostov K, Engel JN. Pseudomonas aeruginosa-mediated damage requires distinct receptors at the apical and basolateral surfaces of the polarized epithelium. Infect Immun 78: 939-953, 2010.
8. Bucior I, Pielage JF, Engel JN. Pseudomonas aeruginosa pili and flagella mediate distinct binding and signaling events at the apical and basolateral surface of airway epithelium. PLoS Pathog 8: e1002616, 2012.
9. Burness CB, Keating GM. Mannitol dry powder for inhalation: in patients with cystic fibrosis. Drugs 72: 1411-1421, 2012.
10. Chabre YM, Giguere D, Blanchard B, Rodrigue J, Rocheleau S, Neault M, Rauthu S, Papadopoulos A, Arnold AA, Imberty A, Roy R. Combining glycomimetic and multivalent strategies toward designing potent bacterial lectin inhibitors. Chemistry 17: 6545-6562, 2011.
11. Chemani C, Imberty A, de Bentzmann S, Pierre M, Wimmerova M, Guery BP, Faure K. Role of LecA and LecB lectins in Pseudomonas aeruginosa-induced lung injury and effect of carbohydrate ligands. Infect Immun 77: 2065-2075, 2009.
12. Comolli J, Waite L, Mostov K, Engel JN. The interaction of Pseudomonas aeruginosa pili and asialo-GM1 stimulates epithelial cell cytotoxicity and bacterial internalization. Infect Immun 67: 3207-3214, 1999.
13. Cusumano CK, Pinkner JS, Han Z, Greene SE, Ford BA, Crowley JR, Henderson JP, Janetka JW, Hultgren SJ. Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci Transl Med 3: 109ra115, 2011.
14. de Lonlay P, Seta N. The clinical spectrum of phosphomannose isomerase deficiency, with an evaluation of mannose treatment for CDG-Ib. Biochim Biophys Acta 1792: 841-843, 2009.
15. Diaz MH, Shaver CM, King JD, Musunuri S, Kazzaz JA, Hauser AR. Pseudomonas aeruginosa induces localized immunosuppression during pneumonia. Infect Immun 76: 4414-4421, 2008.
16. Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 180: 802-808, 2009.
17. Fujitani S, Sun HY, Yu VL, Weingarten JA. Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source. Chest 139: 909-919, 2011.
18. Gjoerup J, Hilberg O, Bendstrup E. Inhaled mannitol in the treatment of non-cystic fibrosis bronchiectasis in adults. Respirology 17: 927-932, 2012.
19. Grigorian A, Demetriou M. Manipulating cell surface glycoproteins by targeting N-glycan-galectin interactions. Methods Enzymol 480: 245-266, 2010.
20. Gustke H, Kleene R, Loers G, Nehmann N, Jaehne M, Bartels KM, Jaeger KE, Schachner M, Schumacher U. Inhibition of the bacterial lectins of Pseudomonas aeruginosa with monosaccharides and peptides. Eur J Clin Microbiol Infect Dis 31: 207-215, 2012.
21. Han Z, Pinkner JS, Ford B, Chorell E, Crowley JM, Cusumano CK, Campbell S, Henderson JP, Hultgren SJ, Janetka JW. Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides. J Med Chem 55: 3945-3959, 2012.
22. Hartmann M, Papavlassopoulos H, Chandrasekaran V, Grabosch C, Beiroth F, Lindhorst TK, Rohl C. Inhibition of bacterial adhesion to live human cells: activity and cytotoxicity of synthetic mannosides. FEBS Lett 586: 1459-1465, 2012.
23. Hauber HP, Schulz M, Pforte A, Mack D, Zabel P, Schumacher U. Inhalation with fucose and galactose for treatment of Pseudomonas aeruginosa in cystic fibrosis patients. Int J Med Sci 5: 371-376, 2008.
24. Hay ID, Remminghorst U, Rehm BH. MucR, a novel membraneassociated regulator of alginate biosynthesis in Pseudomonas aeruginosa. Appl Environ Microbiol 75: 1110-1120, 2009.
25. Hijazi MH, MacIntyre NR. Advances in infection control: ventilatorassociated pneumonia. Semin Respir Crit Care Med 21: 245-262, 2000.
26. Hirche TO, Benabid R, Deslee G, Gangloff S, Achilefu S, Guenounou M, Lebargy F, Hancock RE, Belaaouaj A. Neutrophil elastase mediates innate host protection against Pseudomonas aeruginosa. J Immunol 181: 4945-4954, 2008.
27. Jiang X, Abgottspon D, Kleeb S, Rabbani S, Scharenberg M, Wittwer M, Haug M, Schwardt O, Ernst B. Antiadhesion therapy for urinary tract infections-a balanced PK/PD profile proved to be key for success. J Med Chem 55: 4700-4713, 2012.
28. Johansson EM, Crusz SA, Kolomiets E, Buts L, Kadam RU, Cacciarini M, Bartels KM, Diggle SP, Camara M, Williams P, Loris R, Nativi C, Rosenau F, Jaeger KE, Darbre T, Reymond JL. Inhibition and dispersion of Pseudomonas aeruginosa biofilms by glycopeptide dendrimers targeting the fucose-specific lectin LecB. Chem Biol 15: 1249-1257, 2008.
29. Jones AK, Fulcher NB, Balzer GJ, Urbanowski ML, Pritchett CL, Schurr MJ, Yahr TL, Wolfgang MC. Activation of the Pseudomonas aeruginosa AlgU regulon through mucA mutation inhibits cyclic AMP/Vfr signaling. J Bacteriol 192: 5709-5717, 2010.
30. Kadam RU, Bergmann M, Hurley M, Garg D, Cacciarini M, Swiderska MA, Nativi C, Sattler M, Smyth AR, Williams P, Camara M, Stocker A, Darbre T, Reymond JL. A glycopeptide dendrimer inhibitor of the galactose-specific lectin LecA and of Pseudomonas aeruginosa biofilms. Angew Chem Int Ed Engl 50: 10631-10635, 2011.
31. Koh AY, Priebe GP, Pier GB. Virulence of Pseudomonas aeruginosa in a murine model of gastrointestinal colonization and dissemination in neutropenia. Infect Immun 73: 2262-2272, 2005.
32. Looney MR, Nguyen JX, Hu Y, Van Ziffle JA, Lowell CA, Matthay MA. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest 119: 3450-3461, 2009.
33. Mandell GL, Bennett JE, Dolin R. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Churchill Livingstone/Elsevier, 2010.
34. Mathee K, Ciofu O, Sternberg C, Lindum PW, Campbell JI, Jensen P, Johnsen AH, Givskov M, Ohman DE, Molin S, Hoiby N, Kharazmi A. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology 145: 1349-1357, 1999.
35. Perron GG, Kryazhimskiy S, Rice DP, Buckling A. Multidrug-therapy and evolution of antibiotic resistance: when order matters. Appl Environ Microbiol 78: 6137-6142. 2012.
36. Rhim AD, Stoykova LI, Trindade AJ, Glick MC, Scanlin TF. Altered terminal glycosylation and the pathophysiology of CF lung disease. J Cyst Fibros 3, Suppl 2: 95-96, 2004.
37. Sayem SM, Manzo E, Ciavatta L, Tramice A, Cordone A, Zanfardino A, De Felice M, Varcamonti M. Anti-biofilm activity of an exopolysaccharide from a sponge-associated strain of Bacillus licheniformis. Microb Cell Fact 10: 74, 2011.
38. Sun HY, Fujitani S, Quintiliani R, Yu VL. Pneumonia due to Pseudomonas aeruginosa: part II: antimicrobial resistance, pharmacodynamic concepts, and antibiotic therapy. Chest 139: 1172-1185, 2011.
39. Tian E, Ten Hagen KG. Recent insights into the biological roles of mucin-type O-glycosylation. Glycoconj J 26: 325-334, 2009.
40. von Bismarck P, Schneppenheim R, Schumacher U. Successful treatment of Pseudomonas aeruginosa respiratory tract infection with a sugar solution-a case report on a lectin based therapeutic principle. Klin Padiatr 213: 285-287, 2001.
41. Xia B, Royall JA, Damera G, Sachdev GP, Cummings RD. Altered O-glycosylation and sulfation of airway mucins associated with cystic fibrosis. Glycobiology 15: 747-775, 2005.